Supernus Pharmaceuticals Files 8-K
Ticker: SUPN · Form: 8-K · Filed: 2025-01-27T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, financial-reporting, regulatory-filing
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K, mostly standard financial exhibits. Nothing major to see here.
AI Summary
On January 27, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No new financial figures or significant business updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Supernus Pharmaceuticals is making standard disclosures to the SEC, which is important for investors to stay informed about the company's regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any new risks or significant events.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- January 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report Other Events and Financial Statements and Exhibits as of January 27, 2025.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 27, 2025.
In which state was Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for Supernus Pharmaceuticals, Inc.?
The principal executive office address is 9715 Key West Ave, Rockville, MD 20850.
Does this filing indicate any specific new business developments or financial results?
Based on the provided excerpt, this filing primarily concerns routine disclosures of financial statements and exhibits, and does not detail specific new business developments or financial results.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-27 16:20:37
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20250127.htm (8-K) — 28KB
- ex-991xqelbreelabelupdatep.htm (EX-99.1) — 22KB
- image_0.jpg (GRAPHIC) — 5KB
- 0001356576-25-000002.txt ( ) — 184KB
- supn-20250127.xsd (EX-101.SCH) — 2KB
- supn-20250127_lab.xml (EX-101.LAB) — 21KB
- supn-20250127_pre.xml (EX-101.PRE) — 12KB
- supn-20250127_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 27, 2025, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing a label update for its non-stimulate attention deficit hyperactivity disorder treatment, Qelbree, to include new pharmacodynamic data and information for breastfeeding women. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated January 27, 2025 furnished as an Exhibit pursuant to Item 8.01 hereof. Exhibit 104 — The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: January 27, 2025 By: /s/ Timothy Dec Timothy Dec Senior Vice-President and Chief Financial Officer 3